Nephros Inc.

Nephros Inc.

Nephros Inc. was incorporated in 1997 but traces its operational origins to 2009, when it began commercializing ultrafiltration technology originally conceived at Lawrence Livermore National Laboratory. Robert Banks, a veteran of small-cap public-company management, assumed the role of CEO in 2019 after serving as a director. The company went public via a reverse merger in 2004, then weathered a near-death period during the 2008 financial crisis before pivoting into its current commercial model. Today, it trades on Nasdaq under the symbol NEPH and is headquartered in South Orange, New Jersey. The firm’s strategy rests on two channels: water filtration for infection control in hospitals and long-term-care facilities, and dialysate water purification for hemodialysis providers. Under the brand AETHER, Nephros markets point-of-use and in-line filters that capture bacteria, endotoxins, and other particulates. Its dialysis filters are cleared by the FDA for use in Water and Dialysis Water Systems, addressing the heightened regulatory scrutiny around biofilm and legionella. Key end-markets include acute-care hospitals and outpatient dialysis clinics operated by national chains, which generate repeat purchases as filters can require replacement every 90 days. Nephros employs under 50 people and reported total revenue of roughly $10 million in fiscal 2023, reflecting an asset-light, outsourced manufacturing model. Banks has periodically raised capital through public offerings, including a registered direct offering in early 2023 to fund working capital and potential acquisitions. Beyond the U.S., the company holds CE Mark certification for certain filters sold in Europe through distribution agreements. A small but durable moat exists in its regulatory approvals—each filter line requires FDA or equivalent clearance tied to a specific end-use, creating a barrier for generic competitors. In October 2023, Nephros completed a 1-for-25 reverse stock split to regain Nasdaq compliance (per the firm, October 2023), reflecting the small-cap, transitional nature of the business. The structural differentiator is Nephros’ dual status as both a commercial supplier and a public-microcap survivor. Unlike most revenue-stage medical-device companies, Nephros operates primarily as a consumables business rather than a capital-equipment seller, aligning its incentives with ongoing facility safety compliance rather than large one-time installations. This makes the business closer in form to a sterilization-by-subscription model—one that still lacks earnings predictability, but represents a genuine alternative to traditional capital-heavy water-treatment equipment providers.